Another lovely RNs5 Jun 2025 07:12
The Company has now completed the synthesis of development candidates, marking the third of seven stages in the SVN-SDN-014 translational development plan. This latest phase involved the synthesis of a focused set of compounds for subsequent preclinical characterisation, including pharmacological and toxicological profiling.
The remaining stages for the programme are as follows:
1. In-vitro screening for SERT, DAT and NET re-absorption inhibition
2. In-vitro screening for SERT, DAT and NET release - expected to complete by the end of July 2025
3. Pre-clinical animal testing
4. Lead candidate selection - expected by the end of Q3 2025